{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T18:40:29Z","timestamp":1790707229462,"version":"4.1.0"},"reference-count":60,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,2,8]]},"DOI":"10.7759\/cureus.103234","type":"journal-article","created":{"date-parts":[[2026,2,9]],"date-time":"2026-02-09T04:54:49Z","timestamp":1770612889000},"source":"Crossref","is-referenced-by-count":1,"title":["The Benefits and Risks of Glucagon-Like Peptide-1 Receptor Agonists on Ocular Diseases: A Narrative Review"],"prefix":"10.7759","author":[{"given":"Jacky Xiao Feng","family":"Huang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joshua","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hunain","family":"Ahmad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jason","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samaantar","family":"Joshi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adil","family":"Yousaf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rishita","family":"Pemminati","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sudhakar","family":"Pemminati","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"crossref","DOI":"10.7573\/dic.212283","article-title":"A clinical review of GLP-1 receptor agonists: efficacy and safety in diabetes and beyond","volume":"4","author":"Prasad-Reddy L","year":"2015","unstructured":"Prasad-Reddy L, Isaacs D. A clinical review of GLP-1 receptor agonists: efficacy and safety in diabetes and beyond. Drugs Context. 2015, 4:212283.","journal-title":"Drugs Context"},{"key":"ref2","article-title":"Glucagon-like peptide-1 receptor agonists as a non-surgical alternative to bariatric surgery for weight loss: a review","volume":"18","author":"Steven C","year":"2026","unstructured":"Steven C, Skylynn T, Bardya H, et al.. Glucagon-like peptide-1 receptor agonists as a non-surgical alternative to bariatric surgery for weight loss: a review. Cureus. 2026, 18:e100704.","journal-title":"Cureus"},{"key":"ref3","article-title":"GLP-1 injectable use among adults with diagnosed diabetes: United States, 2024","author":"Vahratian A","year":"2025","unstructured":"Vahratian A, Warren A. GLP-1 injectable use among adults with diagnosed diabetes: United States, 2024. NCHS Data Brief. 2025, 1-8.","journal-title":"NCHS Data Brief"},{"key":"ref4","article-title":"A system-based review on effects of glucagon-like peptide-1 receptor agonists: benefits vs risks","volume":"17","author":"Fadel LP","year":"2025","unstructured":"Fadel LP, Thao G, Chitre T, et al.. A system-based review on effects of glucagon-like peptide-1 receptor agonists: benefits vs risks. Cureus. 2025, 17:e78575.","journal-title":"Cureus"},{"key":"ref5","unstructured":"McKinsey & Company. What\u2019s the market size for GLP-1s?. (2025). Accessed. January 20, 2026: https:\/\/www.mckinsey.com\/featured-insights\/mckinsey-explainers\/what-are-glp-1-medications."},{"key":"ref6","doi-asserted-by":"crossref","DOI":"10.1001\/jamaophthalmol.2024.2296","article-title":"Risk of nonarteritic anterior ischemic optic neuropathy in patients prescribed semaglutide","volume":"142","author":"Hathaway JT","year":"2024","unstructured":"Hathaway JT, Shah MP, Hathaway DB, et al.. Risk of nonarteritic anterior ischemic optic neuropathy in patients prescribed semaglutide. JAMA Ophthalmol. 2024, 142:732-9.","journal-title":"JAMA Ophthalmol"},{"key":"ref7","doi-asserted-by":"crossref","DOI":"10.1016\/j.jdiacomp.2022.108255","article-title":"Progression of retinopathy with glucagon-like peptide-1 receptor agonists with cardiovascular benefits in type 2 diabetes - a systematic review and meta-analysis","volume":"36","author":"Yoshida Y","year":"2022","unstructured":"Yoshida Y, Joshi P, Barri S, Wang J, Corder AL, O'Connell SS, Fonseca VA. Progression of retinopathy with glucagon-like peptide-1 receptor agonists with cardiovascular benefits in type 2 diabetes - a systematic review and meta-analysis. J Diabetes Complications. 2022, 36:108255.","journal-title":"J Diabetes Complications"},{"key":"ref8","article-title":"Risk of retinal vein occlusion between glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes. A retrospective cohort study","volume":"5","author":"Pan SY","year":"2025","unstructured":"Pan SY, Weng CH, Tsai SF, et al.. Risk of retinal vein occlusion between glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes. A retrospective cohort study. Ophthalmol Sci. 2025, 5:100734.","journal-title":"Ophthalmol Sci"},{"key":"ref9","doi-asserted-by":"crossref","DOI":"10.1167\/iovs.15-19006","article-title":"Protective effect of a GLP-1 analog on ischemia-reperfusion induced blood-retinal barrier breakdown and inflammation","volume":"57","author":"Gon\u00e7alves A","year":"2016","unstructured":"Gon\u00e7alves A, Lin CM, Muthusamy A, et al.. Protective effect of a GLP-1 analog on ischemia-reperfusion induced blood-retinal barrier breakdown and inflammation. Invest Ophthalmol Vis Sci. 2016, 57:2584-92.","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"ref10","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2020.108271","article-title":"GLP-1 receptor agonist NLY01 reduces retinal inflammation and neuron death secondary to ocular hypertension","volume":"33","author":"Sterling JK","year":"2020","unstructured":"Sterling JK, Adetunji MO, Guttha S, et al.. GLP-1 receptor agonist NLY01 reduces retinal inflammation and neuron death secondary to ocular hypertension. Cell Rep. 2020, 33:108271.","journal-title":"Cell Rep"},{"key":"ref11","doi-asserted-by":"crossref","DOI":"10.1016\/j.ophtha.2024.08.023","article-title":"Comparative effects of glucagon-like peptide 1 receptor agonists and metformin on glaucoma risk in patients with type 2 diabetes","volume":"132","author":"Muayad J","year":"2025","unstructured":"Muayad J, Loya A, Hussain ZS, Chauhan MZ, Alsoudi AF, De Francesco T, Ahmed II. Comparative effects of glucagon-like peptide 1 receptor agonists and metformin on glaucoma risk in patients with type 2 diabetes. Ophthalmology. 2025, 132:271-9.","journal-title":"Ophthalmology"},{"key":"ref12","doi-asserted-by":"crossref","DOI":"10.1016\/j.ajo.2024.08.030","article-title":"Association between glucagon-like peptide-1 receptor agonists exposure and intraocular pressure change. GLP-1 receptor agonists and intraocular pressure change","volume":"269","author":"Hallaj S","year":"2025","unstructured":"Hallaj S, Halfpenny W, Chuter BG, Weinreb RN, Baxter SL, Cui QN. Association between glucagon-like peptide-1 receptor agonists exposure and intraocular pressure change. GLP-1 receptor agonists and intraocular pressure change. Am J Ophthalmol. 2025, 269:255-65.","journal-title":"Am J Ophthalmol"},{"key":"ref13","doi-asserted-by":"crossref","DOI":"10.1111\/dom.13172","article-title":"Semaglutide, reduction in glycated haemoglobin and the risk of diabetic retinopathy","volume":"20","author":"Vilsb\u00f8ll T","year":"2018","unstructured":"Vilsb\u00f8ll T, Bain SC, Leiter LA, et al.. Semaglutide, reduction in glycated haemoglobin and the risk of diabetic retinopathy. Diabetes Obes Metab. 2018, 20:889-97.","journal-title":"Diabetes Obes Metab"},{"key":"ref14","doi-asserted-by":"crossref","DOI":"10.1016\/j.diabet.2017.10.014","article-title":"Early worsening of diabetic retinopathy after rapid improvement of blood glucose control in patients with diabetes","volume":"44","author":"Feldman-Billard S","year":"2018","unstructured":"Feldman-Billard S, Larger \u00c9, Massin P. Early worsening of diabetic retinopathy after rapid improvement of blood glucose control in patients with diabetes. Diabetes Metab. 2018, 44:4-14.","journal-title":"Diabetes Metab"},{"key":"ref15","doi-asserted-by":"crossref","DOI":"10.1007\/s13300-021-01190-z","article-title":"Early worsening of retinopathy in type\u00a01 and type\u00a02 diabetes after rapid improvement in glycaemic control: a systematic review","volume":"13","author":"Akil H","year":"2022","unstructured":"Akil H, Burgess J, Nevitt S, Harding SP, Alam U, Burgess P. Early worsening of retinopathy in type\u00a01 and type\u00a02 diabetes after rapid improvement in glycaemic control: a systematic review. Diabetes Ther. 2022, 13:1-23.","journal-title":"Diabetes Ther"},{"key":"ref16","doi-asserted-by":"crossref","DOI":"10.1016\/j.survophthal.2023.07.002","article-title":"GLP-1 receptor agonists and diabetic retinopathy: a meta-analysis of randomized clinical trials","volume":"68","author":"Kapoor I","year":"2023","unstructured":"Kapoor I, Sarvepalli SM, D'Alessio D, Grewal DS, Hadziahmetovic M. GLP-1 receptor agonists and diabetic retinopathy: a meta-analysis of randomized clinical trials. Surv Ophthalmol. 2023, 68:1071-83.","journal-title":"Surv Ophthalmol"},{"key":"ref17","doi-asserted-by":"crossref","DOI":"10.1186\/s40942-024-00620-x","article-title":"Once-weekly semaglutide doubles the five-year risk of nonarteritic anterior ischemic optic neuropathy in a Danish cohort of 424,152 persons with type 2 diabetes","volume":"10","author":"Grauslund J","year":"2024","unstructured":"Grauslund J, Taha AA, Molander LD, Kawasaki R, M\u00f6ller S, H\u00f8jlund K, Stokholm L. Once-weekly semaglutide doubles the five-year risk of nonarteritic anterior ischemic optic neuropathy in a Danish cohort of 424,152 persons with type 2 diabetes. Int J Retina Vitreous. 2024, 10:97.","journal-title":"Int J Retina Vitreous"},{"key":"ref18","doi-asserted-by":"crossref","DOI":"10.1016\/j.dsx.2022.102696","article-title":"Glucagon-like peptide 1-receptor agonists and A1c: Good for the heart but less so for the eyes?","volume":"17","author":"Albert SG","year":"2023","unstructured":"Albert SG, Wood EM, Ahir V. Glucagon-like peptide 1-receptor agonists and A1c: Good for the heart but less so for the eyes?. Diabetes Metab Syndr. 2023, 17:102696.","journal-title":"Diabetes Metab Syndr"},{"key":"ref19","doi-asserted-by":"crossref","DOI":"10.2337\/dc20-1815","article-title":"HbA(1c) change and diabetic retinopathy during GLP-1 receptor agonist cardiovascular outcome trials: a meta-analysis and meta-regression","volume":"44","author":"Bethel MA","year":"2021","unstructured":"Bethel MA, Diaz R, Castellana N, Bhattacharya I, Gerstein HC, Lakshmanan MC. HbA(1c) change and diabetic retinopathy during GLP-1 receptor agonist cardiovascular outcome trials: a meta-analysis and meta-regression. Diabetes Care. 2021, 44:290-6.","journal-title":"Diabetes Care"},{"key":"ref20","article-title":"Glucose transport, transporters and metabolism in diabetic retinopathy","volume":"1870","author":"Zhang C","year":"2024","unstructured":"Zhang C, Gu L, Xie H, et al.. Glucose transport, transporters and metabolism in diabetic retinopathy. Biochim Biophys Acta Mol Basis Dis. 2024, 1870:166995.","journal-title":"Biochim Biophys Acta Mol Basis Dis"},{"key":"ref21","doi-asserted-by":"crossref","DOI":"10.1161\/ATVBAHA.111.227389","article-title":"Acute exposure to low glucose rapidly induces endothelial dysfunction and mitochondrial oxidative stress: role for AMP kinase","volume":"32","author":"Wang J","year":"2012","unstructured":"Wang J, Alexanian A, Ying R, et al.. Acute exposure to low glucose rapidly induces endothelial dysfunction and mitochondrial oxidative stress: role for AMP kinase. Arterioscler Thromb Vasc Biol. 2012, 32:712-20.","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"ref22","article-title":"Effects of acute hypoglycemia on inflammatory and pro-atherothrombotic biomarkers in individuals with type 1 diabetes and healthy individuals","volume":"33","author":"Joy NG","year":"2010","unstructured":"Joy NG, Hedrington MS, Briscoe VJ, Tate DB, Ertl AC, Davis SN. Effects of acute hypoglycemia on inflammatory and pro-atherothrombotic biomarkers in individuals with type 1 diabetes and healthy individuals. Diabetes Care. 2010, 33:1529-35.","journal-title":"Diabetes Care"},{"key":"ref23","doi-asserted-by":"crossref","DOI":"10.1002\/acn3.52300","article-title":"Liraglutide for idiopathic intracranial hypertension: a real-world propensity score-matched study","volume":"12","author":"Azzam AY","year":"2025","unstructured":"Azzam AY, Essibayi MA, Vaishnav D, et al.. Liraglutide for idiopathic intracranial hypertension: a real-world propensity score-matched study. Ann Clin Transl Neurol. 2025, 12:746-55.","journal-title":"Ann Clin Transl Neurol"},{"key":"ref24","article-title":"The blood-retinal barrier in ocular pathologies: an updated narrative review","volume":"46","author":"Hang Z","year":"2026","unstructured":"Hang Z, Li Y, Ren W, Du H. The blood-retinal barrier in ocular pathologies: an updated narrative review. Int Ophthalmol. 2026, 46:10.","journal-title":"Int Ophthalmol"},{"key":"ref25","article-title":"Microvascular effects of glucagon-like peptide-1 receptor agonists in type 2 diabetes: a meta-analysis of randomized controlled trials","volume":"54","author":"Dicembrini I","year":"2017","unstructured":"Dicembrini I, Nreu B, Scatena A, Andreozzi F, Sesti G, Mannucci E, Monami M. Microvascular effects of glucagon-like peptide-1 receptor agonists in type 2 diabetes: a meta-analysis of randomized controlled trials. Acta Diabetol. 2017, 54:933-41.","journal-title":"Acta Diabetol"},{"key":"ref26","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page MJ","year":"2021","unstructured":"Page MJ, McKenzie JE, Bossuyt PM, et al.. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021, 372:n71.","journal-title":"BMJ"},{"key":"ref27","article-title":"Diabetic retinopathy for the non-ophthalmologist","volume":"22","author":"Fung TH","year":"2022","unstructured":"Fung TH, Patel B, Wilmot EG, Amoaku WM. Diabetic retinopathy for the non-ophthalmologist. Clin Med (Lond). 2022, 22:112-6.","journal-title":"Clin Med (Lond)"},{"key":"ref28","doi-asserted-by":"crossref","DOI":"10.1016\/j.redox.2020.101799","article-title":"Oxidative stress and diabetic retinopathy: molecular mechanisms, pathogenetic role and therapeutic implications","volume":"37","author":"Kang Q","year":"2020","unstructured":"Kang Q, Yang C. Oxidative stress and diabetic retinopathy: molecular mechanisms, pathogenetic role and therapeutic implications. Redox Biol. 2020, 37:101799.","journal-title":"Redox Biol"},{"key":"ref29","article-title":"Incidence and progression of diabetic retinopathy in patients treated with glucagon-like peptide-1 receptor agonists versus sodium-glucose cotransporter 2 inhibitors: a population-based cohort study","volume":"26","author":"Lin DS","year":"2024","unstructured":"Lin DS, Lo HY, Huang KC, Lin TT, Lee JK, Lin LY. Incidence and progression of diabetic retinopathy in patients treated with glucagon-like peptide-1 receptor agonists versus sodium-glucose cotransporter 2 inhibitors: a population-based cohort study. Diabetes Obes Metab. 2024, 26:4386-96.","journal-title":"Diabetes Obes Metab"},{"key":"ref30","article-title":"Impact of GLP-1 agonists and SGLT-2 inhibitors on diabetic retinopathy progression: an aggregated electronic health record data study","volume":"265","author":"Wai KM","year":"2024","unstructured":"Wai KM, Mishra K, Koo E, Ludwig CA, Parikh R, Mruthyunjaya P, Rahimy E. Impact of GLP-1 agonists and SGLT-2 inhibitors on diabetic retinopathy progression: an aggregated electronic health record data study. Am J Ophthalmol. 2024, 265:39-47.","journal-title":"Am J Ophthalmol"},{"key":"ref31","doi-asserted-by":"crossref","DOI":"10.1007\/s00125-024-06132-5","article-title":"Risk of diabetic retinopathy and diabetic macular oedema with sodium-glucose cotransporter 2 inhibitors and glucagon-like peptide 1 receptor agonists in type 2 diabetes: a real-world data study from a global federated database","volume":"67","author":"Eleftheriadou A","year":"2024","unstructured":"Eleftheriadou A, Riley D, Zhao SS, et al.. Risk of diabetic retinopathy and diabetic macular oedema with sodium-glucose cotransporter 2 inhibitors and glucagon-like peptide 1 receptor agonists in type 2 diabetes: a real-world data study from a global federated database. Diabetologia. 2024, 67:1271-82.","journal-title":"Diabetologia"},{"key":"ref32","doi-asserted-by":"crossref","DOI":"10.1007\/s00125-025-06466-8","article-title":"Early worsening of diabetic retinopathy in individuals with type 2 diabetes treated with tirzepatide: a real-world cohort study","volume":"68","author":"Buckley AJ","year":"2025","unstructured":"Buckley AJ, Tan GD, Gruszka-Goh M, Scanlon PH, Ansari I, Suliman SG. Early worsening of diabetic retinopathy in individuals with type 2 diabetes treated with tirzepatide: a real-world cohort study. Diabetologia. 2025, 68:2069-76.","journal-title":"Diabetologia"},{"key":"ref33","article-title":"Risk of diabetic retinopathy between sodium-glucose cotransporter-2 inhibitors and glucagon-like peptide-1 receptor agonists","volume":"47","author":"Lin TY","year":"2023","unstructured":"Lin TY, Kang EY, Shao SC, et al.. Risk of diabetic retinopathy between sodium-glucose cotransporter-2 inhibitors and glucagon-like peptide-1 receptor agonists. Diabetes Metab J. 2023, 47:394-404.","journal-title":"Diabetes Metab J"},{"key":"ref34","doi-asserted-by":"crossref","DOI":"10.2337\/dc17-2280","article-title":"Glucagon-like peptide 1 receptor agonists and the risk of incident diabetic retinopathy","volume":"41","author":"Douros A","year":"2018","unstructured":"Douros A, Filion KB, Yin H, Yu OH, Etminan M, Udell JA, Azoulay L. Glucagon-like peptide 1 receptor agonists and the risk of incident diabetic retinopathy. Diabetes Care. 2018, 41:2330-8.","journal-title":"Diabetes Care"},{"key":"ref35","article-title":"Semaglutide and cardiovascular outcomes in patients with type 2 diabetes","volume":"375","author":"Marso SP","year":"2016","unstructured":"Marso SP, Bain SC, Consoli A, et al.. Semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med. 2016, 375:1834-44.","journal-title":"N Engl J Med"},{"key":"ref36","doi-asserted-by":"crossref","DOI":"10.2337\/db16-1364","article-title":"GLP-1R as a target for the treatment of diabetic retinopathy: friend or foe?","volume":"66","author":"Sim\u00f3 R","year":"2017","unstructured":"Sim\u00f3 R, Hern\u00e1ndez C. GLP-1R as a target for the treatment of diabetic retinopathy: friend or foe?. Diabetes. 2017, 66:1453-60.","journal-title":"Diabetes"},{"key":"ref37","doi-asserted-by":"crossref","DOI":"10.1007\/s40261-021-01110-w","article-title":"Semaglutide and diabetic retinopathy risk in patients with type 2 diabetes mellitus: a meta-analysis of randomized controlled trials","volume":"42","author":"Wang F","year":"2022","unstructured":"Wang F, Mao Y, Wang H, Liu Y, Huang P. Semaglutide and diabetic retinopathy risk in patients with type 2 diabetes mellitus: a meta-analysis of randomized controlled trials. Clin Drug Investig. 2022, 42:17-28.","journal-title":"Clin Drug Investig"},{"key":"ref38","doi-asserted-by":"publisher","DOI":"10.1155\/2007\/61038","article-title":"The polyol pathway as a mechanism for diabetic retinopathy: attractive, elusive, and resilient","volume":"2007","author":"Lorenzi M","year":"2007","unstructured":"Lorenzi M. The polyol pathway as a mechanism for diabetic retinopathy: attractive, elusive, and resilient. Exp Diabetes Res. 2007, 2007:61038. 10.1155\/2007\/61038","journal-title":"Exp Diabetes Res"},{"key":"ref39","doi-asserted-by":"publisher","DOI":"10.1111\/j.1464-5491.2008.02650.x","article-title":"A dramatic deterioration in diabetic retinopathy with improvement in glycated haemoglobin (HbA(1c)) on exenatide treatment","volume":"26","author":"Brooks AM","year":"2009","unstructured":"Brooks AM, Lissett CA. A dramatic deterioration in diabetic retinopathy with improvement in glycated haemoglobin (HbA(1c)) on exenatide treatment. Diabet Med. 2009, 26:190. 10.1111\/j.1464-5491.2008.02650.x","journal-title":"Diabet Med"},{"key":"ref40","doi-asserted-by":"crossref","DOI":"10.2337\/dc25-0690","article-title":"Gradual titration of semaglutide results in better treatment adherence and fewer adverse events: a randomized controlled open-label pilot study examining a 16-week flexible titration regimen versus label-recommended 8-week semaglutide titration regimen","volume":"48","author":"Eldor R","year":"2025","unstructured":"Eldor R, Avraham N, Rosenberg O, et al.. Gradual titration of semaglutide results in better treatment adherence and fewer adverse events: a randomized controlled open-label pilot study examining a 16-week flexible titration regimen versus label-recommended 8-week semaglutide titration regimen. Diabetes Care. 2025, 48:1607-11.","journal-title":"Diabetes Care"},{"key":"ref41","doi-asserted-by":"crossref","DOI":"10.3390\/jcm13206269","article-title":"The effect of glucagon-like-peptide-1 receptor agonists on diabetic retinopathy progression, central subfield thickness, and response to intravitreal injections","volume":"13","author":"Michaeli T","year":"2024","unstructured":"Michaeli T, Khateb S, Levy J. The effect of glucagon-like-peptide-1 receptor agonists on diabetic retinopathy progression, central subfield thickness, and response to intravitreal injections. J Clin Med. 2024, 13:6269.","journal-title":"J Clin Med"},{"key":"ref42","article-title":"Vitreous hemorrhage during GLP-1 receptor agonist treatment","volume":"63","author":"Kim DS","year":"2023","unstructured":"Kim DS, Latollari A, Khaimova R. Vitreous hemorrhage during GLP-1 receptor agonist treatment. J Am Pharm Assoc (2003). 2023, 63:976-9.","journal-title":"J Am Pharm Assoc (2003)"},{"key":"ref43","doi-asserted-by":"crossref","DOI":"10.1111\/dom.13484","article-title":"Glucagon-like peptide-1 receptor agonists and microvascular outcomes in type 2 diabetes: a systematic review and meta-analysis","volume":"21","author":"Avgerinos I","year":"2019","unstructured":"Avgerinos I, Karagiannis T, Malandris K, et al.. Glucagon-like peptide-1 receptor agonists and microvascular outcomes in type 2 diabetes: a systematic review and meta-analysis. Diabetes Obes Metab. 2019, 21:188-93.","journal-title":"Diabetes Obes Metab"},{"key":"ref44","article-title":"Liraglutide and cardiovascular outcomes in type 2 diabetes","volume":"375","author":"Marso SP","year":"2016","unstructured":"Marso SP, Daniels GH, Brown-Frandsen K, et al.. Liraglutide and cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2016, 375:311-22.","journal-title":"N Engl J Med"},{"key":"ref45","article-title":"The effect of glucagon-like peptide-1 receptor agonists on diabetic retinopathy at a tertiary care center","volume":"4","author":"Joo JH","year":"2024","unstructured":"Joo JH, Sharma N, Shaia J, Wu AK, Skugor M, Singh RP, Rachitskaya AV. The effect of glucagon-like peptide-1 receptor agonists on diabetic retinopathy at a tertiary care center. Ophthalmol Sci. 2024, 4:100547.","journal-title":"Ophthalmol Sci"},{"key":"ref46","article-title":"Worsening of diabetic retinopathy with rapid improvement in systemic glucose control: a review","volume":"21","author":"Bain SC","year":"2019","unstructured":"Bain SC, Klufas MA, Ho A, Matthews DR. Worsening of diabetic retinopathy with rapid improvement in systemic glucose control: a review. Diabetes Obes Metab. 2019, 21:454-66.","journal-title":"Diabetes Obes Metab"},{"key":"ref47","doi-asserted-by":"crossref","DOI":"10.1111\/dom.16316","article-title":"Use of semaglutide and risk of non-arteritic anterior ischemic optic neuropathy: a Danish-Norwegian cohort study","volume":"27","author":"Simonsen E","year":"2025","unstructured":"Simonsen E, Lund LC, Ernst MT, et al.. Use of semaglutide and risk of non-arteritic anterior ischemic optic neuropathy: a Danish-Norwegian cohort study. Diabetes Obes Metab. 2025, 27:3094-3103.","journal-title":"Diabetes Obes Metab"},{"key":"ref48","article-title":"Semaglutide and nonarteritic anterior ischemic optic neuropathy","volume":"143","author":"Cai CX","year":"2025","unstructured":"Cai CX, Hribar M, Baxter S, et al.. Semaglutide and nonarteritic anterior ischemic optic neuropathy. JAMA Ophthalmol. 2025, 143:304-14.","journal-title":"JAMA Ophthalmol"},{"key":"ref49","article-title":"Bilateral non-arteritic anterior ischemic optic neuropathy following weight loss from semaglutide (Ozempic): a case report","volume":"49","author":"Karam EZ","year":"2024","unstructured":"Karam EZ, Johnson N, Sensenbrenner S. Bilateral non-arteritic anterior ischemic optic neuropathy following weight loss from semaglutide (Ozempic): a case report. Neuro-Ophthalmology. 2024, 49:313-9.","journal-title":"Neuro-Ophthalmology"},{"key":"ref50","article-title":"Semaglutide-inducing non-arteritic anterior ischemic optic neuropathy and ipsilateral blindness -a rare presentation","volume":"6","author":"Mao B","year":"2025","unstructured":"Mao B, Goberdhan S, Mumtaz U, Tahir S, Hussain ST. Semaglutide-inducing non-arteritic anterior ischemic optic neuropathy and ipsilateral blindness -a rare presentation. Journal of Clinical Cardiology. 2025, 6:33-6.","journal-title":"Journal of Clinical Cardiology"},{"key":"ref51","unstructured":"European Medicines Agency (EMA). PRAC concludes eye condition NAION is a very rare side effect of semaglutide medicines Ozempic, Rybelsus and Wegovy. (2025). Accessed. January 28, 2026: https:\/\/www.ema.europa.eu\/en\/news\/prac-concludes-eye-condition-naion-very-rare-side-effect-semaglutide-medicines-ozem...."},{"key":"ref52","doi-asserted-by":"crossref","DOI":"10.1080\/14796678.2025.2511412","article-title":"Semaglutide: a key medication for managing cardiovascular-kidney-metabolic syndrome","volume":"21","author":"MacIsaac RJ","year":"2025","unstructured":"MacIsaac RJ. Semaglutide: a key medication for managing cardiovascular-kidney-metabolic syndrome. Future Cardiol. 2025, 21:663-83.","journal-title":"Future Cardiol"},{"key":"ref53","doi-asserted-by":"crossref","DOI":"10.3390\/cells11213362","article-title":"Diabetic macular edema: current understanding, molecular mechanisms and therapeutic implications","volume":"11","author":"Zhang J","year":"2022","unstructured":"Zhang J, Zhang J, Zhang C, Zhang J, Gu L, Luo D, Qiu Q. Diabetic macular edema: current understanding, molecular mechanisms and therapeutic implications. Cells. 2022, 11:3362.","journal-title":"Cells"},{"key":"ref54","doi-asserted-by":"publisher","DOI":"10.1136\/bjophthalmol-2021-319232","article-title":"Glucagon-like peptide 1 receptor agonist use is associated with reduced risk for glaucoma","volume":"107","author":"Sterling J","year":"2023","unstructured":"Sterling J, Hua P, Dunaief JL, Cui QN, VanderBeek BL. Glucagon-like peptide 1 receptor agonist use is associated with reduced risk for glaucoma. Br J Ophthalmol. 2023, 107:215-20. 10.1136\/bjophthalmol-2021-319232","journal-title":"Br J Ophthalmol"},{"key":"ref55","doi-asserted-by":"crossref","DOI":"10.1002\/edm2.70059","article-title":"Incidence of glaucoma in type 2 diabetes patients treated with GLP-1 receptor agonists: a systematic review and meta-analysis","volume":"8","author":"Asif M","year":"2025","unstructured":"Asif M, Asif A, Rahman UA, et al.. Incidence of glaucoma in type 2 diabetes patients treated with GLP-1 receptor agonists: a systematic review and meta-analysis. Endocrinol Diabetes Metab. 2025, 8:e70059.","journal-title":"Endocrinol Diabetes Metab"},{"key":"ref56","article-title":"Sodium-glucose cotransporter 2 inhibitors and risk of retinal vein occlusion among patients with type 2 diabetes: a propensity score-matched cohort study","volume":"44","author":"Lee MK","year":"2021","unstructured":"Lee MK, Kim B, Han K, et al.. Sodium-glucose cotransporter 2 inhibitors and risk of retinal vein occlusion among patients with type 2 diabetes: a propensity score-matched cohort study. Diabetes Care. 2021, 44:2419-26.","journal-title":"Diabetes Care"},{"key":"ref57","doi-asserted-by":"crossref","DOI":"10.1186\/s10194-023-01631-z","article-title":"Treatment with GLP-1 receptor agonists is associated with significant weight loss and favorable headache outcomes in idiopathic intracranial hypertension","volume":"24","author":"Krajnc N","year":"2023","unstructured":"Krajnc N, Itariu B, Macher S, et al.. Treatment with GLP-1 receptor agonists is associated with significant weight loss and favorable headache outcomes in idiopathic intracranial hypertension. J Headache Pain. 2023, 24:89.","journal-title":"J Headache Pain"},{"key":"ref58","doi-asserted-by":"crossref","DOI":"10.1093\/brain\/awad003","article-title":"The effect of GLP-1RA exenatide on idiopathic intracranial hypertension: a randomized clinical trial","volume":"146","author":"Mitchell JL","year":"2023","unstructured":"Mitchell JL, Lyons HS, Walker JK, et al.. The effect of GLP-1RA exenatide on idiopathic intracranial hypertension: a randomized clinical trial. Brain. 2023, 146:1821-30.","journal-title":"Brain"},{"key":"ref59","doi-asserted-by":"crossref","DOI":"10.1002\/edm2.70019","article-title":"Efficacy of tirzepatide dual GIP\/GLP-1 receptor agonist in patients with idiopathic intracranial hypertension. A real-world propensity score-matched study","volume":"8","author":"Azzam AY","year":"2025","unstructured":"Azzam AY, Essibayi MA, Farkas N, et al.. Efficacy of tirzepatide dual GIP\/GLP-1 receptor agonist in patients with idiopathic intracranial hypertension. A real-world propensity score-matched study. Endocrinol Diabetes Metab. 2025, 8:e70019.","journal-title":"Endocrinol Diabetes Metab"},{"key":"ref60","doi-asserted-by":"crossref","DOI":"10.1001\/jamaneurol.2025.2020","article-title":"GLP-1 receptor agonists in idiopathic intracranial hypertension","volume":"82","author":"Sioutas GS","year":"2025","unstructured":"Sioutas GS, Mualem W, Reavey-Cantwell J, Rivet DJ 2nd. GLP-1 receptor agonists in idiopathic intracranial hypertension. JAMA Neurol. 2025, 82:887-94.","journal-title":"JAMA Neurol"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/443624-the-benefits-and-risks-of-glucagon-like-peptide-1-receptor-agonists-on-ocular-diseases-a-narrative-review","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,9]],"date-time":"2026-02-09T04:54:56Z","timestamp":1770612896000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/443624-the-benefits-and-risks-of-glucagon-like-peptide-1-receptor-agonists-on-ocular-diseases-a-narrative-review"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,8]]},"references-count":60,"URL":"https:\/\/doi.org\/10.7759\/cureus.103234","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2026,2,8]]}}}